An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Dose-Finding Study of Pacritinib in Patients With Leukemia Previously Treated With Ruxolitinib
Sponsor: CTI BioPharma
Enrolling: Male and Female Patients
IRB Number: AAAR9195
U.S. Govt. ID: NCT03165734
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out what dose of pacritinib is safest and works best for participants. Pacritinib is an experimental drug, which is a drug that is being tested and is not currently approved by the Food and Drug Administration (FDA) in the US. The study will be conducted at about 85 study clinics in North America, Europe, Israel and South Korea and about 150 people participate in this study.
This study is closed
Investigator
Mark Heaney, MD, PhD
Do You Qualify?
Are you 18 years old? Yes No
Do you have Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytopenia Myelofibrosis? Yes No
Do you have a life expectancy of 6 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE